After positive early data, Pfizer, BioNTech CEOs sound off on coronavirus vaccine timelines HHS allocates another $4B in COVID-19 relief funds to rural facilities, safety-net hospitals Boehringer Ingelheim-backed COVID researchers identify new antibodies to fight the virus Aetna, Give an Hour team up to offer free counseling to frontline health workers Philips taps BioIntelliSense’s symptom-tracking sticker for COVID-19, other chronic diseases Healthfirst accelerates launch of its member app due to COVID-19 Avalere: ACA's exchange enrollment could increase by 1M due to COVID-19 job losses Biopharma roundup: Gilead releases shaky remdesivir findings; BI-partnered researchers ID 28 antibody hopefuls Harbour BioMed nabs meaty C round as cancer, COVID-19 work draws investors Featured Story | By Eric Sagonowsky Pfizer and BioNTech are still gearing up for their massive late-stage vaccine trial, but their helmsmen are talking up potential green lights later this year. In separate interviews, Pfizer CEO Albert Bourla and BioNTech CEO Ugur Sahin said their mRNA candidate could be ready to file for approvals in the fall or winter. read more |
| |
|---|
|
| | [Webinar] Zero Deviation Mindset: Achieving Agility in Cell Therapy Supply Chains Tuesday, July 21 | 10am ET / 7am PT Join Thermo Fisher Scientific and Pluristem Therapeutics as we discuss lessons learned in developing the just-in-time supply chain for their phase III hip fracture study, and how these lessons are being used in their current efforts to treat severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome (ARDS) in the United States. Register Now. |
Top Stories By Robert King Health and Human Services is allocating approximately $3 billion to safety-net hospitals and another $1 billion in COVID-19 relief funds to certain rural providers and others in small metropolitan areas. read more By Arlene Weintraub By studying the antibody response to COVID-19 in 12 patients and immune cells from 48 healthy people, German researchers uncovered 28 antibodies that neutralize the virus. They're now working with Boehringer Ingelheim to advance the drugs into clinical testing. read more By Paige Minemyer Give an Hour is an organization that has traditionally provided free mental healthcare to veterans with post-traumatic stress disorder, anxiety and other behavioral health needs. Amid COVID-19, however, the team realized that another group of “heroes” needed their help, too—frontline healthcare workers. read more By Conor Hale Philips announced plans to integrate BioIntelliSense’s health-tracking sticker into its remote patient monitoring programs, designed to observe at-risk patients after they head home from the hospital. read more By Paige Minemyer As COVID-19 led to significant increases in the demand for digital health, New York-based non-profit insurer Healthfirst accelerated the launch of its new app for its 1.5 million members. read more By Robert King The Affordable Care Act’s insurance exchanges could add more than 1 million new customers because of the COVID-19 pandemic, and the numbers could stick. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Gilead released shaky findings on its antiviral remdesivir comparing phase 3 trial data with a historical patient cohort. An Italian study found that many recovered COVID patients still experience symptoms months on. Plus, the European Commission said advanced purchase talks for COVID vaccines would not be hampered by the U.K.'s withdrawal from the scheme. read more By Ben Adams Just a few months after a series B-plus worth $75 million, U.S.-China biotech Harbour BioMed has nabbed a major $102.8 million series C, with an IPO surely not far behind. read more |
